| Literature DB >> 12176114 |
Douglas J MacNeil1, Andrew D Howard, Xiaoming Guan, Tung M Fong, Ravi P Nargund, Maria A Bednarek, Mark T Goulet, David H Weinberg, Alison M Strack, Donald J Marsh, Howard Y Chen, Chun-Pyn Shen, Airu S Chen, Charles I Rosenblum, Tanya MacNeil, Michael Tota, Euan D MacIntyre, Lex H T Van der Ploeg.
Abstract
Five G-protein-coupled melanocortin receptors (MC(1)-MC(5)) are expressed in mammalian tissues. The melanocortin receptors support diverse physiological functions, including the regulation of hair color, adrenal function, energy homeostasis, feed efficiency, sebaceous gland lipid production and immune and sexual function. The melanocortins (adrenocorticotropic hormone (ACTH), alpha-melanocyte-stimulating hormone (alpha-MSH), beta-MSH and gamma-MSH) are agonist peptide ligands for the melanocortin receptors and these peptides are processed from the pre-prohormone proopiomelanocortin (POMC). Peptide antagonists for the melanocortin MC(1), MC(3) and MC(4) receptors include agouti-related protein (AgRP) and agouti. Diverse lines of evidence, including genetic and pharmacological data obtained in rodents and humans, support a role for the melanocortin MC(3) and MC(4) receptors in the regulation of energy homeostasis. Recent advances in the development of potent and selective peptide and non-peptide melanocortin receptor ligands are anticipated to help unravel the roles for the melanocortin receptors in humans and to accelerate the clinical use of small molecule melanocortin mimetics.Entities:
Mesh：
Substances：
Year: 2002 PMID： 12176114 DOI： 10.1016/s0014-2999(02)01989-1
Source DB: PubMed Journal: Eur J Pharmacol ISSN： 0014-2999 Impact factor: 4.432